10X Genomics Files for $100 Million IPO

August 20, 2019

10X Genomics filed the paperwork for its IPO on 8/19/19. The company will raise up to $100 Million. 10X provides instruments, consumables and software for or analyzing biological systems at a resolution and scale that "matches the complexity of biology." The company will trade on NASDAQ under the symbol "TXG."

10X provides solutions and products for:

  • Single Cell Gene Expression
  • Single Cell Immune Profiling
  • Single Cell ATAC
  • Spatial Cell Expression
  • Single Cell CNV
  • Linked-Reads Genomics

According to the filing prospectus, the company's revenue grew by 106% in 2018 compared to 2017 ($71.1 million to $146.3 million). For the six months ended June 30, 2018 and 2019, respectively, revenue grew at an annual growth rate of 85%. However, the company generated net losses of $18.8 million and $112.5 million for 2017 and 2018.

10X generated net losses of $21.6 million and $14.5 million for the six months ended June 30, 2018 and 2019, respectively. The $14.5 million net loss included a $15.9 million accrual for estimated royalties related to ongoing litigation according to its prospectus.

In January of 2019, the company announced the closing of a $35 Million Series D round. The round was led by Meritech Capital with Fidelity and Wells Fargo participating.

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.